[
    [
        {
            "time": "",
            "original_text": "A股药企一季报：11家净利超十亿，32家销售费用率过半",
            "features": {
                "keywords": [
                    "A股药企",
                    "一季报",
                    "净利",
                    "销售费用率"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "A股药企一季报：11家净利超十亿，32家销售费用率过半",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "山东药玻扩产丨复星PD-1产线通过GMP丨复星、恒瑞优先审批丨华海新药丨蓝帆手套投产丨恒瑞、君实、上海医药临床许可丨贝达临床申请",
            "features": {
                "keywords": [
                    "山东药玻",
                    "复星",
                    "恒瑞",
                    "华海",
                    "蓝帆",
                    "临床许可",
                    "GMP"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "山东药玻扩产丨复星PD-1产线通过GMP丨复星、恒瑞优先审批丨华海新药丨蓝帆手套投产丨恒瑞、君实、上海医药临床许可丨贝达临床申请",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 7,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "交银国际：上海医药维持买入评级 目标价18.40港元",
            "features": {
                "keywords": [
                    "交银国际",
                    "上海医药",
                    "买入评级",
                    "目标价"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "交银国际：上海医药维持买入评级 目标价18.40港元",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        }
    ]
]